The Role of Serum Lipid Profile, Fasting Blood Sugar, and Body Mass Index on Recurrence and Metastasis in Patients With Estrogen Receptor‑Positive Breast Cancer: A Case–Control Study Publisher



Mohammadbeigy I¹ ; Khalilian MS¹ ; Najafizadeh N^{2, 3} ; Moazam E³ ; Hemati S^{2, 3} ; Zeinalian M^{1, 3, 4} Show Affiliations
Source: Journal of Research in Medical Sciences Published:2023

Abstract

Background: Breast cancer (BC) is the leading cause of cancer death in women. The current study is designed to evaluate the association of lipid profiles, FBS, and body mass index (BMI) with BC recurrence and metastasis. Materials and Methods: This is a case–control study on estrogen receptor‑positive BC patients in Isfahan Province, Central Iran, between 2008 and 2020. The control group was patients who had no evidence of recurrence or metastasis at least 1 year after the end of chemotherapy and hormone therapy. The case group was patients with evidence of metastasis or recurrence within 1 year after the end of chemotherapy and hormone therapy. Fasting blood sugar (FBS), total cholesterol (Chol), triglyceride (TG), high‑density lipoprotein (HDL), and low‑density lipoprotein (LDL) were measured before treatment, after chemotherapy, and after hormone therapy as well as BMI in the case and control groups. Results: There were 108 patients in the case and 119 patients in the control group with a mean age of 50.72 ± 13.26 and 51.91 ± 11.79, respectively. There were no meaningful differences between the case and control groups regarding serum FBS, Chol, TG, HDL, LDL, and BMI. Conclusion: We found no association between serum FBS, lipid profile, and BMI at initial diagnosis and BC recurrence or metastasis. © 2023 Journal of Research in Medical Sciences | Published by Wolters Kluwer - Medknow.